CMS’ innovation center can’t design payment models to test drug price controls until after Congress decides what it’s going to do on drug pricing, Center for Medicare and Medicaid Innovation Director Elizabeth Fowler said Tuesday (Oct. 5), and the center also can’t design demos for Aduhelm until CMS determines a national Medicare coverage policy for the Alzheimer’s drug. HHS’ drug price control plan calls for multiple innovation center demonstrations to control drug prices. They include models that target rebates and...